Jubilant Revenues Flat In Q2 On LSI Business Decline, FDA action
LSI To Be Demerged, Founder Cos Merged In Restructuring
Jubilant reports higher second-quarter profits as it defers tax liability while revenues remain flat on the back of a decline in LSI business and FDA action at two manufacturing units.
You may also be interested in...
Continuing sartans crisis, new product launches in US help Alembic post strong Q2 performance despite slowdown in other markets.
Jubilant’s board is considering whether to create separate entities for its Pharmaceuticals and Life Science Ingredients business segments to give each greater focus.
Yet another valsartan approved as quality/shortage crisis unfolds, while warning letters hit firms on poor root cause investigations and supply chain issues, and FDA investigators procure shirt-button candid cameras.